TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36609257

Group type: EXPERIMENTAL
Intervention: Information about the acute illness
Number of subjects: 7488

Group type: EXPERIMENTAL
Intervention: Age, gender, and geriatric characteristics
Number of subjects: 7488

Group type: EXPERIMENTAL
Intervention: Decisions to withhold LST
Number of subjects: 7488

Group type: EXPERIMENTAL
Intervention: Decisions to withdraw LST
Number of subjects: 7488
Study: 36609279

Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment of malaria in schoolchildren (IPTsc) using dihydroartemisinin-piperaquine (DP) given three times a year in four-month intervals.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 24
Study: 36609335

Group type: EXPERIMENTAL
Intervention: Teacher training programme and mindfulness programme delivered to students
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Education as usual (Control)
Number of subjects: 1100
Study: 36609349

Group type: EXPERIMENTAL
Intervention: Shared Decision Engagement System (SharES) with iCanDecide +/- emotional support module
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Clinician Dashboard reviewed by surgeons/clinicians
Number of subjects: 700
Study: 36609389

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole plus trastuzumab (PLT)
Number of subjects: 26
Study: 36609655

Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SSA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SSA) + Pegvisomant (PEG)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pegvisomant (PEG)
Number of subjects: 23
Study: 36609807

Group type: EXPERIMENTAL
Intervention: CCNU/TMZ
Number of subjects: 1

Group type: COMPARATOR
Intervention: TMZ
Number of subjects: 1
Study: 36609834

Group type: EXPERIMENTAL
Intervention: Multi-Task Training Group (MTTG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single-Task Training Group (STTG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 42
Study: 36609978

Group type: EXPERIMENTAL
Intervention: VDR rs7975232 polymorphism
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: ACC haplotype (order of rs731236, rs7975232, rs1544410)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: rs7975232 CC genotype
Number of subjects: 151
Study: 36610390

Group type: EXPERIMENTAL
Intervention: AZD1222 vaccination
Number of subjects: 3058
Study: 36610464

Group type: EXPERIMENTAL
Intervention: Icatibant (30 mg doses/d for 3 consecutive days plus standard care)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard care alone (Control)
Number of subjects: 73
Study: 36610886

Group type: EXPERIMENTAL
Intervention: Postoperative intensity-modulated radiotherapy (IMRT)
Number of subjects: 3203

Group type: COMPARATOR
Intervention: No postoperative IMRT
Number of subjects: 3203
Study: 36610891

Group type: EXPERIMENTAL
Intervention: Sunitinib (monotherapy or combined with local treatment)
Number of subjects: 62
Study: 36611210

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (maintaining hemoglobin concentrations greater than 9 g/dL)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (maintaining hemoglobin concentrations greater than 7 g/dL)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 794

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 794
Study: 36611211

Group type: EXPERIMENTAL
Intervention: Early nutrition support (< 48 h)
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 1206

Group type: COMPARATOR
Intervention: No early nutrition
Number of subjects: 1206
Study: 36611312

Group type: EXPERIMENTAL
Intervention: MRD-positive B-ALL patients
Number of subjects: 267

Group type: COMPARATOR
Intervention: MRD-negative B-ALL patients
Number of subjects: 267
Study: 36611327

Group type: COMPARATOR
Intervention: Healthy control group (C)
Number of subjects: 143
Study: 36611550

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention group (control)
Number of subjects: 50
Study: 36612650

Group type: EXPERIMENTAL
Intervention: Monthly telephonic interventions based on motivational interviewing and collaborative care strategies
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 384
Study: 36612844

Group type: EXPERIMENTAL
Intervention: Training programme for developing social and personal skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched individuals not participating in the training
Number of subjects: 0
Study: 36614923

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: gabapentin
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: oral preventive drugs
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: oral preventive drugs and onabotulinumtoxinA
Number of subjects: 183
Study: 36614948

Group type: EXPERIMENTAL
Intervention: V-01D-351
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: BV-01-B5
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: V-01
Number of subjects: 56

Group type: COMPARATOR
Intervention: ICV
Number of subjects: 56
Study: 36615077

Group type: EXPERIMENTAL
Intervention: Small Step early intervention program
Number of subjects: 11
Study: 36615174

Group type: EXPERIMENTAL
Intervention: Aronia supplementation (150 mg anthocyanins daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 36617389

Group type: COMPARATOR
Intervention: Fixed dose of insulin for a fixed range of carbohydrates (FD group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Precise dose of insulin for a precise number of carbohydrates using an insulin-to-carbohydrate ratio (ICR group)
Number of subjects: 24
Study: 36617391

Group type: EXPERIMENTAL
Intervention: PROGRESS-CTO perforation risk score
Number of subjects: 4566
Study: 36617406

Group type: EXPERIMENTAL
Intervention: Prefrail (defined by Fried phenotype)
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: Frail (defined by Fried phenotype)
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: Frailty (assessed by Fried phenotype and FI)
Number of subjects: 19114
Study: 36617410

Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HF-SCS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-frequency spinal cord stimulation (LF-SCS)
Number of subjects: 50
Study: 36617413

Group type: EXPERIMENTAL
Intervention: EIoT-ergo group
Number of subjects: 35
Study: 36617554

Group type: EXPERIMENTAL
Intervention: GD2-specific 4SCAR-T cells (infused through intravenous administration alone or combined with intracavitary administration)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GD2-specific 4SCAR-T cells
Number of subjects: 8
Study: 36617560

Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711) 180 mg orally once daily
Number of subjects: 43
Study: 36617561

Group type: EXPERIMENTAL
Intervention: Prenatal social support measured using the ENRICHD Social Support Inventory (ESSI)
Number of subjects: 301
Study: 36617729

Group type: EXPERIMENTAL
Intervention: Lower-extremity perfusion assessment (LEPA) model
Number of subjects: 57
Study: 36617848

Group type: EXPERIMENTAL
Intervention: Conservative treatment for midportion Achilles tendinopathy
Number of subjects: 54
Study: 36617964

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 101
Study: 36618438

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 55
Study: 36618582

Group type: EXPERIMENTAL
Intervention: 18 G Tuohy needle
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 25 G Tuohy needle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Loss of Resistance Technique (LORT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoroscopy only method
Number of subjects: 40
Study: 36618690

Group type: EXPERIMENTAL
Intervention: Mediterranean diet pattern (MDP) with nutrition education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean diet pattern (MDP)
Number of subjects: 0
Study: 36618749

Group type: EXPERIMENTAL
Intervention: Comics-based intervention
Number of subjects: 35
Study: 36618900

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily, Lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle, Rituximab 375 mg/m2
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 89
Study: 36618925

Group type: EXPERIMENTAL
Intervention: Qishen granules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36619318

Group type: EXPERIMENTAL
Intervention: Periodic fasting (n=73, 35.6%) for 40.4±20.6 years prior to COVID-19 diagnosis.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Non-fasters (n=132, 64.4%) who did not engage in periodic fasting.
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Periodic fasting (n=73, 35.6%)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Non-fasters (n=132, 64.4%)
Number of subjects: 205
Study: 36619332

Group type: EXPERIMENTAL
Intervention: Daily intake of 57 g Jarlsberg cheese (J-group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Daily intake of 25-50 g Camembert (C-group)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Daily intake of 57 g Jarlsberg cheese (after switching from C-group)
Number of subjects: 66
Study: 36619613

Group type: EXPERIMENTAL
Intervention: NEU-SFL values measured after admission
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Change in NEU-SFL values during hospitalization
Number of subjects: 1852
Study: 36619619

Group type: EXPERIMENTAL
Intervention: Functionality-based writing tasks
Number of subjects: 451

Group type: COMPARATOR
Intervention: Creative writing tasks (control)
Number of subjects: 451
Study: 36619630

Group type: EXPERIMENTAL
Intervention: Femoral arterial site for MAP measurement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radial arterial site for MAP measurement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-dose norepinephrine (≥0.3 μg/kg/min)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Norepinephrine (≥0.1 μg/kg/min)
Number of subjects: 80
Study: 36619856

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 811
Study: 36620297

Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Health controls (HC)
Number of subjects: 157
Study: 36620354

Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention group (DIGI)
Number of subjects: 2907

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2907
Study: 36620625

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 3831

Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 3831

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3831
Study: 36620632

Group type: EXPERIMENTAL
Intervention: Intravenous antibacterial prophylaxis (IV ABX) with compliance rates of 96.6% and biologic envelope hydrated in antibiotics (77.1%)
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Biologic envelope hydrated in antibiotics
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Antibacterial envelopes without adjunct IV ABX
Number of subjects: 1102
Study: 36620634

Group type: EXPERIMENTAL
Intervention: Edoxaban administered through PEG at approved doses
Number of subjects: 12
Study: 36620637

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TEE)
Number of subjects: 90
Study: 36620646

Group type: EXPERIMENTAL
Intervention: One-stent strategy
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: T-stenting
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: V-stenting
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Two-stent strategy
Number of subjects: 905
Study: 36620770

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard-dose atorvastatin (not specified)
Number of subjects: 130
Study: 36620891

Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of active vs sham
Number of subjects: 30
Study: 36620892

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once daily
Number of subjects: 685
Study: 36620965

Group type: EXPERIMENTAL
Intervention: Inclisiran (300 mg subcutaneous, twice-yearly)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Evolocumab (140 mg subcutaneous, every 2 weeks for 360 days, then inclisiran twice-yearly)
Number of subjects: 497
Study: 36621000

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on Days 1 and 8 of each 21-day treatment cycle until disease progression/unacceptable toxicity
Number of subjects: 80
Study: 36621036

Group type: EXPERIMENTAL
Intervention: Written preparatory information booklet ('The SUMMIT Study: Next Steps')
Number of subjects: 2014
Study: 36621142

Group type: EXPERIMENTAL
Intervention: Previous systemic therapies (specifically protein kinase inhibitors)
Number of subjects: 3290
Study: 36621145

Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid (DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 36621212

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study: 36621265

Group type: EXPERIMENTAL
Intervention: Social Cognitive and active learning theory-based classroom cooking with tasting lessons, active recess games, cooking with tasting food promotion during school lunch, family nights, and take-home intervention reinforcements; a 7-month program delivered by a trained intervention team.
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Evening events for families.
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Online survey for parents regarding recipe preparation.
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Take-home activity sheets for students.
Number of subjects: 851
Study: 36621410

Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 1720

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1720
Study: 36621554

Group type: EXPERIMENTAL
Intervention: Co-ingestion of flavan-3-ols and cocoa methylxanthines (theobromine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theobromine
Number of subjects: 10
Study: 36621751

Group type: EXPERIMENTAL
Intervention: mt-sDNA second round testing
Number of subjects: 2758

Group type: COMPARATOR
Intervention: mt-sDNA first round testing
Number of subjects: 2758
Study: 36621757

Group type: EXPERIMENTAL
Intervention: Robot-assisted lobectomy (RAL)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Video-assisted lobectomy (VAL)
Number of subjects: 320
Study: 36621827

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1028
Study: 36621830

Group type: EXPERIMENTAL
Intervention: DS-1205c monotherapy (200-1200 mg BID) followed by combination therapy with DS-1205c (800 mg BID) and gefitinib (250 mg once daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DS-1205c (800 mg BID) in combination with gefitinib (250 mg once daily)
Number of subjects: 20
Study: 36621880

Group type: EXPERIMENTAL
Intervention: Genome-informed risk assessment (GIRA) report
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Return of high-risk GIRA
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Integrated genetic risk assessment
Number of subjects: 25000
Study: 36622121

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 218
Study: 36622148

Group type: EXPERIMENTAL
Intervention: 3HP and dolutegravir
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3HP alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoniazid with neither dolutegravir nor rifapentine
Number of subjects: 30
Study: 36622252

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36622402

Group type: EXPERIMENTAL
Intervention: Test formulation (60 mg FTD/TPI, 20 mg tablet, 3 tablets)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference formulation (Lonsurf)
Number of subjects: 32
Study: 36622424

Group type: EXPERIMENTAL
Intervention: Modified surgical anchor placement
Number of subjects: 13
Study: 36622458

Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 237

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 237
Study: 36622462

Group type: COMPARATOR
Intervention: no-basic Therapy Intensity Level (TIL)
Number of subjects: 2320

Group type: EXPERIMENTAL
Intervention: extreme Therapy Intensity Level (eTIL)
Number of subjects: 2320

Group type: COMPARATOR
Intervention: mild-moderate Therapy Intensity Level (TIL)
Number of subjects: 2320

Group type: EXPERIMENTAL
Intervention: Therapy Intensity Level (TIL)
Number of subjects: 2320
Study: 36622539

Group type: EXPERIMENTAL
Intervention: Tecarfarin 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tecarfarin 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tecarfarin 30 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tecarfarin 40 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tecarfarin (all doses)
Number of subjects: 40
Study: 36622552

Group type: EXPERIMENTAL
Intervention: TAVI with SAPIEN 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 0
Study: 36622567

Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WHR ≥ 0.9 in men and WHR ≥ 0.85 in women)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: General obesity (BMI ≥ 30)
Number of subjects: 394
Study: 36622653

Group type: EXPERIMENTAL
Intervention: Internet-delivered parent-child interaction therapy (iPCIT) for 20 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Internet-delivered parent-child interaction therapy (iPCIT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Referrals as usual (RAU)
Number of subjects: 150
Study: 36622674

Group type: EXPERIMENTAL
Intervention: Enhanced pharmacy care with a focus on health-related social needs
Number of subjects: 364

Group type: COMPARATOR
Intervention: Usual pharmacy care focused on medication adherence
Number of subjects: 364
Study: 36622685

Group type: EXPERIMENTAL
Intervention: Endovascular Brain-Computer Interface (BCI)
Number of subjects: 5
Study: 36622724

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraception
Number of subjects: 314704
Study: 36622726

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 321

Group type: COMPARATOR
Intervention: School-as-usual control group
Number of subjects: 321
Study: 36622777

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 63
Study: 36622798

Group type: EXPERIMENTAL
Intervention: Daily PrEP dosing (90 days) followed by 1 to 7 doses/week (90 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: edPrEP adherence classification
Number of subjects: 0
Study: 36622879

Group type: EXPERIMENTAL
Intervention: Mindfulness mobile app intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 36622896

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 70

Group type: COMPARATOR
Intervention: Secondary wound healing
Number of subjects: 70
Study: 36622954

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Rowing Training (FESRT) for 12 weeks, 3 sessions/week at 70-85% of peak heart rate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 21
Study: 36623230

Group type: EXPERIMENTAL
Intervention: 70-Gy once-daily radiotherapy
Number of subjects: 638

Group type: COMPARATOR
Intervention: 45-Gy twice-daily radiotherapy
Number of subjects: 638
Study: 36623234

Group type: EXPERIMENTAL
Intervention: Personalized body-worn alcohol dispenser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 36623241

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 6 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for 1 year followed by surveillance without surgical resection
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pembrolizumab for less than 1 year
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Spatial immune profiling with imaging mass cytometry
Number of subjects: 35
Study: 36623246

Group type: COMPARATOR
Intervention: Whole-breast irradiation (WBI)
Number of subjects: 3309

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy APBI (38.5 Gy/10 fraction twice daily)
Number of subjects: 3309
Study: 36623247

Group type: EXPERIMENTAL
Intervention: PAE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAE + MD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAE + MD + TD
Number of subjects: 0
Study: 36623318

Group type: EXPERIMENTAL
Intervention: Dual-energy CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positron emission tomography (PET)
Number of subjects: 0
Study: 36623419

Group type: EXPERIMENTAL
Intervention: Anodal tDCS targeting left sensorimotor cortex (LSMC) during visual attention for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study: 36623423

Group type: EXPERIMENTAL
Intervention: Very-low-density lipoprotein (VLDL)-TG concentrations
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TG within lipoprotein subclasses, particularly VLDL
Number of subjects: 50
Study: 36623515

Group type: EXPERIMENTAL
Intervention: Cisplatin plus veliparib
Number of subjects: 320

Group type: COMPARATOR
Intervention: Cisplatin plus placebo
Number of subjects: 320